Nevada Medicaid – Molina Healthcare

Forteo® (teriparatide)
Prior Authorization Request Form

Please provide the information below. Please print your answer, attach supporting documentation, sign, date, and return to our office as soon as possible to expedite this request. **FAX responses to: (844) 259-1689. Phone: (833) 685-2103.**

Member Information (required)			**Provider Information (required)**		
Member Name:			Provider Name:		
Molina ID#:			NPI#:	Specialty:	
Date of Birth:			Office Phone:		
Street Address:			Office Fax:		
City:	State:	Zip:	Office Street Address:		
Phone:			City:	State:	Zip:

Medication Information (required)		
Medication Name:	Strength:	Dosage Form:
❑ Check if requesting brand ❑ Check if request is for initial therapy ❑ Check if request is for recertification of therapy	Directions for Use:	

Clinical Information (required)

Select the diagnosis below:

- ❑ Diagnosis of postmenopausal osteoporosis or osteopenia
- ❑ Diagnosis of primary or hypogonadal osteoporosis or osteopenia
- ❑ Diagnosis of glucocorticoid-induced osteoporosis (recipient has a documented history of prednisone or its equivalent at a dose greater than or equal to 5 mg/day for greater than or equal to three months).
- ❑ Other diagnosis:_____ ICD-10 Code(s): _____

Drug-Specific Information (required)

- ❑ The recipient's Bone Mineral Density (BMD) T-score is -2.5 or lower in the lumbar spine, femoral neck, total hip or radius (one-third radius site).
- ❑ The recipient has a BMD T-score between -1.0 and -2.5 in the lumbar spine, femoral neck, total hip or radius (one-third radius site).
- ❑ The recipient has documented history of low-trauma fracture of the hip, spine, proximal humerus, pelvis or distal forearm.
- ❑ The recipient has documented trial and failure, contraindication, or intolerance to one anti-resorptive treatment (e.g., alendronate, risedronate, zoledronic acid, Prolia® [denosumab]).
- ❑ The recipient has a FRAX 10-year probability of a major osteoporotic fracture at 20% or more in the U.S., or the country-specific threshold in other countries or regions.
- ❑ The recipient has a FRAX 10-year probability of a hip fracture at 3% or more in the U.S., or the country-specific threshold in other countries or regions.
- ❑ Treatment duration of parathyroid hormones has not exceeded a total of 24 months during the recipient's lifetime.

Attach any additional comments, diagnoses, symptoms, medications tried or failed, or other information the physician feels is important to this review.

Please note: This request may be denied unless all required information is received. For urgent or expedited requests please call (833) 685-2103. This form may be used for non-urgent requests and faxed to (844) 259-1689.

This document and others if attached contain information that is privileged, confidential and/or may contain protected health information (PHI). The Provider named above is required to safeguard PHI by applicable law. The information in this document is for the sole use of Molina Healthcare. Proper consent to disclose PHI between these parties has been obtained. If you received this document by mistake, please know that sharing, copying, distributing or using information in this document is against the law. **If you are not the intended recipient, please notify the sender immediately.**